Dr. Surena Matin discusses significance of OLYMPUS trial, Jelmyto

Video

“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.

In this video, Surena F. Matin, MD, discusses the significance of the OLYMPUS trial of mitomycin-containing reverse thermal hydrogel (Jelmyto) for low-grade upper tract urothelial carcinoma and how the treatment addresses an unmet therapeutic need. Final results of the OLYMPUS trial were presented at the 2020 Society of Urologic Oncology annual meeting. Matin is a professor urology at the University of Texas MD Anderson Cancer Center, Houston.

Related Videos
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
Illustration of AI | Image Credit: © Tierney - stock.adobe.com
DNA illustration | Image Credit: © BillionPhotos.com - stock.adobe.com
Mara R. Holton, MD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.